AVTX | Ticker Profile - Titan Protect

AVTX

Avalo Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$13.10

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$830M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.50

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-88.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$45.00

+244% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 11 analysts covering this stock

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

https://www.avalotx.com

Country: United States Employees: 33 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.599

Good returns relative to risk taken

Kelly Fraction

0.0359

Modest edge detected — smaller position warranted

Calmar Ratio

0.208

Drawdown risk outweighs the returns — higher risk profile

Annual Return

15.7%

Historical annualised return based on price data

Max Drawdown

-75.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.79

Less volatile than the market — more defensive

52W High

$24.27

46% below the year high

52W Low

$3.58

266% above the year low

Avg Volume

1,477,770

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

11.9%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.57

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.48

Conservative use of debt — low financial risk

Current Ratio

7.66

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

7.07

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-134,164.4%

Profit from core operations before interest and tax

Free Cash Flow

$-23,247,124

Negative — the business is spending more than it generates

Revenue (TTM)

$59,000

Total revenue over the last 12 months

Net Income

$-84,740,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$60.00

Target Median

$45.00

Target Low

$34.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go